Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer
RegulatorypositiveEnhertuPositive
AI Analysis
Summary
Enhertu received a CHMP recommendation for approval in the EU as an adjuvant treatment for HER2-positive early breast cancer patients with residual disease after neoadjuvant therapy. This positive regulatory action represents a significant milestone for the drug's expanded indication in Europe.
Outcome Details
CHMP recommended approval for adjuvant treatment of HER2 positive early breast cancer with residual disease
Importance:8/10
Sentiment:
0.85
regulatory approvaloncologybreast cancerHER2 positiveadjuvant treatmentEU approvalCHMP recommendation
Related Companies
Read the original article
Published by yahoo_finance on September 18, 2026 12:00 PM